Diagnosing & Treating Psoriasis in Patients with Skin of Color | Pearls from the Experts
During the 2023 Skin of Color Update in New York City, esteemed experts, Dr. Andrew Alexis, Professor of Clinical Dermatology at Weill Cornell Medical College, and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shared their expertise in diagnosing and managing psoriasis in individuals with skin of color …
During the 2023 Skin of Color Update in New York City, esteemed experts, Dr. Andrew Alexis, Professor of Clinical Dermatology at Weill Cornell Medical College, and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shared their expertise in diagnosing and managing psoriasis in individuals with skin of color … 
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. George Han, associate professor of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. There’s a lot of nuance in diagnosing psoriasis in darker skin tones, according to Dr. Han. Learn three components to consider, and why you might want to introduce systemic therapies earlier in this … 
Do implicit bias and race-compliance stereotyping impact clinical decision making in psoriasis? A feasibility study published in the February issue of the Journal of Drugs in Dermatology sought to answer this question.
To learn more about the key findings and takeaways, I interviewed one of the authors, Rithu Srikantha, MD, associate professor of dermatology at the Feinberg School of Medicine/N … 
Explore the February 2024 issue of the Journal of Drugs in Dermatology! Discover groundbreaking research on topics such as novel treatments for melasma, advancements in psoriasis management, gene expression profile (GEP) testing for squamous cell carcinoma, pediatric vitiligo, and many more! Stay ahead of the curve with the latest insights from leading dermatology experts. Straight from the Editor … 
Bimekizumab (Bimzelx®) is a new injectable medication FDA approved for plaque psoriasis. It is the first and only FDA approved IL-17A and IL-17F inhibitor for this disease, but is also being used as an off-label option for other conditions including psoriatic arthritis and hidradenitis suppurativa. This Therapeutic Cheat Sheet will focus on the on and off label uses of bimekizumab.
Bimekizuma …